Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

157

Participants

Timeline

Start Date

January 28, 2014

Primary Completion Date

January 25, 2019

Study Completion Date

May 21, 2019

Conditions
Crohn's Disease
Interventions
DRUG

Vedolizumab

Vedolizumab IV injection

DRUG

Vedolizumab placebo

Vedolizumab placebo-matching IV infusion

Trial Locations (56)

Unknown

Nagoya

Toyota

Hirosaki

Abiko

Kashiwa

Sakura

Matsuyama

Chikushino-shi

Kasuga

Kitakyushu

Takasaki

Fukuyama

Hatsukaichi

Asahikawa

Sapporo

Tomakomai

Akashi

Nishinomiya

Takamatsu

Kamakura

Kawasaki

Sagamihara

Yokohama

Kochi

Sendai

Kurashiki

Moriguchi

Suita

Tokorozawa

Ōtsu

Hamamatsu

Shimotsuke

Adachi-ku

Bunkyo-ku

Chiyoda-ku

Minato-ku

Shinagawa-ku

Shinjuku-ku

Shūnan

Kofu

Chiba

Fukui

Fukuoka

Hiroshima

Kagoshima

Kumamoto

Kyoto

Nagasaki

Niigata

Okayama

Okinawa

Osaka

Ōita

Saga

Saitama

Wakayama

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY